Tag: Biosimilars
India’s biosimilars industry staring at plethora of opportunities
Between now and 2030, biologic products worth US $170 billion will lose patent protection globally, writes Dr Cyrus Karkaria, President – Biotechnology, Lupin Limited
Inflation law drives biologic drugs to outpace small molecules in venture...
According to GlobalData’s Pharma Intelligence Center Deals database, the US biotechs saw 48% or $1.1 billion more in innovator drug venture financing, reaching a total deal value of $3.2 billion in 2023
BioVoice eMagazine June 2023 | Issue 6 | Volume 4
This edition tracks the latest scenario in Indian CRO industry and analyzes whether India can become a hotspot for clinical trials. Key highlights include Expert Insights by Dr Cyrus Karkaria, President- Biotechnology, Lupin and Zoya Brar, Founder, CORE Diagnostics.
Biocon revenue up 59% at Rs 3,929 crore in Q4FY23
The company's revenue in biosimilars is up 114%; research services up 31% and EBITDA at Rs 1,152 crore up 75%
Biocon Biologics’ new mAbs facility receives EU GMP certification for bBevacizumab
This approval reflects Biocon Biologics’ compliance with the highest international regulatory standards and enables the company to continue addressing the needs of patients
Biocon’s Q3 FY23 revenue stands at Rs 3,020 crore, up by...
The company's revenue from operations surged 35% YoY to Rs 2,941 crore for the third quarter under review, compared with Rs 2,174 crore in the last-year period
EU officially allows interchangeability of biosimilars
While interchangeable use of biosimilars is already practiced in many Member States, this joint position harmonizes the EU approach
Lupin & DKSH sign an exclusive licensing & supply agreement to...
According to the agreement, Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved
India tops the chart for approved biosimilars & clinical trials surpassing...
The recent acts and policy changes like the Generic Drug User Fee Act (GDUFA) is expected to positively impact the generics manufacturers in India, deliberations at Pharma IPR India Conference revealed ..................................
Cipla Gulf expands partnership with Alvotech for commercialization of biosimilars in...
The products are developed and manufactured by Alvotech and will be distributed by Cipla Gulf through Australia and New Zealand distribution networks........................